Medicus Pharma shares rationale as CD228V becomes lead development priority

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug conjugate licensed from Pfizer.
For the three months ended September 30, 2026, Medicus reported a net loss of $15.2 million, or $11.64 per share, compared with a loss of $16 million, or $56.18 per share, in the same period last year.
Medicus ended the quarter with $13.1 million in cash, cash equivalents and restricted cash, including $5 million in unrestricted cash and cash equivalents.
Bokhari said the third quarter marked a transformation for Medicus into a precision oncology-focused biotechnology company, with CD228V now its principal development priority. Medicus holds an exclusive worldwide licence to develop, manufacture and commercialize CD228V through a co-development agreement with Pfizer, which has provided $2 million in development funding.
The company is targeting initial clinical proof-of-concept in patients with relapsed, refractory or immunotherapy-resistant melanoma. The program is supported by an existing US investigational new drug application and a first-in-human Phase 1 study.
Medicus believes CD228V could potentially achieve an objective response rate above 30% in melanoma, although that target has yet to be demonstrated in clinical trials. Pfizer also has the option to fund all or part of development costs beginning with the first pivotal trial.
Medicus is also advancing plans to separate its SkinJect business through a proposed business combination with a special purpose acquisition company.
Meanwhile, for Teverelix, the company has submitted a proposed seamless Phase 2b/3 clinical trial protocol to the US Food and Drug Administration for advanced prostate cancer. The study is designed to enrol approximately 608 patients, subject to meeting predefined criteria to proceed.
Rather than fund the Teverelix study itself, Medicus intends to pursue an out-licensing agreement or another strategic partnership to advance the program.
#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CD228V #PrecisionOncology #Biotechnology #CancerResearch #Melanoma #Pfizer #SkinJect #Teverelix #ClinicalTrials #Pharma